Avacta Announces Tumor Shrinkage in Salivary Gland Cancer Patients
Details : AVA6000 is a form of doxorubicin which is chemically modified with Avacta’s pre|CISION platform designed to reduce systemic side effects by targeting release of active chemotherapy in tumour tissue.
Product Name : AVA6000
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : AVA6000
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : LG Chem
Deal Size : $453.5 million
Deal Type : Expanded Partnership
Avacta and LG Chem Life Sciences Expand Partnership
Details : Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.
Product Name : AVA6000
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : AVA6000
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : LG Chem
Deal Size : $453.5 million
Deal Type : Expanded Partnership
Reset All
